EndoCeutics
2989, de la Promenade
Quebec City
Quebec
Canada
Tel: 418-652-0197
11 articles about EndoCeutics
-
Endoceutics® Receives Health Canada Approval for INTRAROSA®
11/6/2019
The first innovative treatment for the treatment of vulvovaginal atrophy with prasterone
-
Endoceutics, Université Laval, and CHU de Québec settle their disputes
3/27/2019
Endoceutics Inc., Université Laval, and CHU de Québec-Université Laval are pleased to announce that they have reached an agreement to resolve all their disputes with respect to economic benefits deriving from research.
-
AMAG Pharmaceuticals and Endoceutics Announce Presentation at the 2018 Annual Meeting of The North American Menopause Society on the Effect of Time Since Menopause, Age and Previous Hormone Therapy on the Response to Intravaginal Prasterone
10/4/2018
Study Suggests that While All Postmenopausal Women Benefit from Treatment with Prasterone (INTRAROSA®), Women Experience Greatest Relief of Moderate to Severe Dyspareunia when started on INTRAROSA® within One to Two Years after Menopause
-
AMAG And EndoCeutics Enter Into An Exclusive U.S. License Agreement For Intrarosa (Prasterone)
2/14/2017
-
EndoCeutics Release: Biopharma Secures $85 Million Credit Facility From CRG
1/11/2017
-
EndoCeutics Release: FDA Approves Intrarosa For Postmenopausal Women Experiencing Pain During Sex
11/17/2016
-
Veristat, Inc. Continues Decade Long Preferred Partnership With EndoCeutics
9/15/2015
-
Up To $330M CAD ($324 Million USD) International Partnership Between Bayer HealthCare Pharmaceuticals And EndoCeutics
10/5/2010
-
Bayer AG Bags Rights to Female Sex Dysfunction Drug from EndoCeutics
5/6/2010
-
Canada's EndoCeutics Lowers IPO Price to $7-$9
5/10/2007
-
Canada's EndoCeutics Files for $75 Million US IPO
2/28/2007